PRMT5 Inhibitor Binding Mode for MTAP-Deleted Tumor Selectivity

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current PRMT5 inhibitors lack selectivity for MTAP-deleted cancer cell lines due to their mechanisms of action, which are either SAM-uncompetitive or SAM-competitive, failing to leverage the accumulation of MTA caused by MTAP-deletion.

Innovation Solution

Development of a PRMT5 inhibitor that binds in an MTA-uncompetitive, non-competitive, or mixed mode manner to target MTAP-deleted cancer cells, leveraging the accumulation of MTA for selective therapy.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If PRMT5 inhibitors with SAM-uncompetitive or SAM-competitive mechanisms are used, then PRMT5 inhibition is achieved, but selectivity for MTAP-deleted cancer cell lines is lost

Engineering Contradiction:

Improveselectivity for MTAP-deleted cancer cell linesVSAvoidbinding mechanism flexibility

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent changes the binding mechanism parameter from SAM-uncompetitive or SAM-competitive to MTA-uncompetitive binding. This parameter change enables the inhibitor to specifically recognize and bind to PRMT5 in the context of MTAP deletion, where MTA accumulates, thereby achieving selectivity for MTAP-deleted cancer cell lines while maintaining PRMT5 inhibition activity

Inventive Principle:

Principle #35Parameter changes

2Reliability

If traditional targeted therapies are developed, then selective targeting of tumor cells is achieved, but tumors with loss-of-function mutations or deletions of tumor suppressor genes cannot be targeted

Engineering Contradiction:

Improvetargeting efficacyVSAvoidapplicability to different tumor types

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent converts the harmful effect of MTAP deletion (which causes accumulation of toxic MTA and collateral damage to nearby genes) into a beneficial therapeutic opportunity. By designing an inhibitor that binds in an MTA-uncompetitive manner, the drug exploits the accumulated MTA in MTAP-deleted cells to achieve selective inhibition of PRMT5, thereby transforming the pathological state into a targetable vulnerability

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

The patent introduces MTA as an intermediary in the binding mechanism. The MTA-uncompetitive binding mode uses MTA (which accumulates in MTAP-deleted cells) as a mediator to enhance the affinity and selectivity of the inhibitor for PRMT5 in the context of MTAP deletion, enabling targeted therapy against tumors that would otherwise be resistant to traditional targeted approaches

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS20260078117A1Compounds and methods of use

Publication Date: 2026.03.19 TANGO THERAPEUTICS INC

AI summary

Compounds are provided according to Formula (1):and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, R3, R4, R6, R7, R8 and n are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.